| abstract |
Disclosed are: a compound represented by formula (I) [wherein m represents a number of 1 or 2; n represents a number of 0 or 1; R1 and R2 independently represent H or a C1-2 alkyl group or may, together with a carbon atom to which both R1 and R2 are attached, form a cyclo ring; the configuration of the hydroxyl group represents one of enantiomers; the dashed line, a, ß, 1 and 2 independently represent the position at which each of -OH and -NH- and a carbon atom on the ring are bound to each other, provided that n represents 0 and the binding position for the hydroxyl group is ß-position when the binding position for -NH- is position-1], a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition and a TRPV1 receptor antagonist each comprising the compound, the salt or the solvate as an active ingredient. |